Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally

JAMA

Volumn 293, Issue 22, 2005, Pages 2767-2775

  Dye, Christopher ^a   Watt, Catherine J ^a   Bleed, Daniel M ^a   Hosseini, S Mehran ^a   Raviglione, Mario C ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA; ARTICLE; COHORT ANALYSIS; DATA ANALYSIS; DISEASE CONTROL; EVALUATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MOLECULAR EVOLUTION; PREVALENCE; PRIORITY JOURNAL; SPUTUM ANALYSIS; TREATMENT OUTCOME; TUBERCULOSIS; UNITED NATIONS; VALIDATION PROCESS; WORLD HEALTH ORGANIZATION; DIRECTLY OBSERVED THERAPY; EASTERN EUROPE; HEALTH; INFECTION CONTROL;

TUBERCULOSTATIC AGENT;

AFRICA; ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASE CONTROL; DIRECTLY OBSERVED THERAPY; EUROPE, EASTERN; HUMANS; INCIDENCE; PREVALENCE; TUBERCULOSIS; WORLD HEALTH;

EID: 20144370344     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.293.22.2767     Document Type: Article

References (53)

1. World Health Organization. Forty-fourth World Health Assembly, Resolutions and Decisions. Geneva, Switzerland: World Health Organization; 1991. WHA44/1991/REC/1.
2. World Bank. World Development Report 1993: Investing in Health. New York, NY: Oxford University Press; 1993.
3. Jamison DT, Mosley WH, Meashem AR, Bobadilla JL. Disease Control Priorities in Developing Countries. New York, NY: Oxford University Press for the World Bank; 1993.
4. Barnum HN. Cost savings from alternative treatments for tuberculosis. Soc Sci Med. 1986;23:847-850.
5. World Health Organization. An Expanded DOTS Framework for Effective Tuberculosis Control. Geneva, Switzerland: WHO; 2002. WHO/CDS/TB/2002.297.
6. World Health Organization. An expanded framework for effective tuberculosis control. Int J Tuberc Lung Dis. 2002;6:378-388.
7. Styblo K, Bumgarner JR. Tuberculosis can be controlled with existing technologies: evidence. Tuberc Surveill Res Unit Prog Rep. 1991;2:60-72.
8. Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet. 1998;352:1886-1891.
9. Borgdorff MW, Floyd K, Broekmans JF. Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. Bull World Health Organ. 2002;80:217-227.
10. Fifty-third World Health Assembly: Stop Tuberculosis Initiative, Report by the Director General. A53/5, 5 May 2000. Geneva, Switzerland: World Health Organization; 2000.
11. Suarez PG, Watt CJ, Alarcon E, et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis. 2001;184:473-478.
12. China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet. 2004;364:417-422.
13. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. Geneva, Switzerland: World Health Organization; 2005.WHO/ HTM/TB/2005.349.
14. United Nations Statistics Division. Millennium indicators database. Available at: http://unstats.un.org /unsd/mi/mi_goals.asp. Accessed November 22, 2004.
15. World Health Organization, International Union Against Tuberculosis and Lung Disease, Royal Netherlands Tuberculosis Association. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis. 2001;5:213-215.
16. Borgdorff M. New measurable indicators for tuberculosis case detection. Emerg Infect Dis. 2004;10:1523-1528.
17. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA. 1999;282:677-686.
18. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163:1009-1021.
19. Frieden T, ed. Toman's Tuberculosis: Case Detection, Treatment and Monitoring. 2nd ed. Geneva, Switzerland: World Health Organization; 2004.
20. Kim SJ, Hong YP, Lew WJ, Yang SC, Lee EG. Incidence of pulmonary tuberculosis in Korean civil servants. Tuberc Lung Dis. 1995;76:534-539.
21. Tuberculosis Research Centre. Trends in the prevalence and incidence of tuberculosis in South India. Int J Tuberc Lung Dis. 2001;5:142-157.
22. Styblo K. Epidemiology of Tuberculosis. 2nd ed. The Hague: Royal Netherlands Tuberculosis Association; 1991.
23. Rieder HL. Epidemiologic Basis of Tuberculosis Control. Paris, France: International Union Against Tuberculosis and Lung Disease; 1999.
24. World Health Organization. Anti-Tuberculosis Drug Resistance in the World: Report No. 3. Geneva, Switzerland: World Health Organization; 2004.
25. Stop TB Department Tuberculosis [World Health Organization Web site]. Available at: http://www.who.int/tb. Accessed May 12, 2005.
26. Corbett EL, Charalambous S, Moloi VM, et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med. 2004;170:673-679.
27. Irawati SR, Arias MS, Voskens J, Kimmerling ME. Hospital DOTS and Linakge (HDL) project for the integration of hospitals in tuberculosis control in Yogyakarta, Indonesia. Int J Tuberc Lung Dis. 2004;11(suppl 1):S98-S99.
28. Elzinga G, Raviglione MC, Maher D. Scale up: meeting targets in global tuberculosis control. Lancet. 2004;363:814-819.
29. UN Millennium Project. Investing in Strategies to Reverse the Global Incidence of TB: Task Force on HIV/AIDS, Malaria, TB, and Access to Essential Medicines. London, England: Earthscan; 2005.
30. Stop TB Partnership. Report on the Meeting of the Second Ad Hoc Committee on the TB Epidemic. Geneva, Switzerland: World Health Organization; 2004. WHO/HTM/STB/2004.28.
31. Espinal M, Kim SJ, Suarez P, et al. Standard shortcourse chemotherapy for drug resistant tuberculosis: treatment outcomes in six countries. JAMA. 2000;283:2537-2545.
32. Suarez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet. 2002;359:1980-1989.
33. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003;348:119-128.
34. Harries AD, Hargreaves NJ, Salaniponi FM. Design of regimens for treating tuberculosis in patients with HIV infection, with particular reference to sub-Saharan Africa. Int J Tuberc Lung Dis. 2001;5:1109-1115.
35. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science. 2003;301:1535-1537.
36. World Health Organization. Interim Policy on Collaborative TB/HIV Activities. Geneva, Switzerland: World Health Organization; 2004. WHO/HTM/TB/2004.330.
37. Zachariah R, Spielmann MP, Harries AD, et al. Passive versus active tuberculosis case finding and isoniazid preventive therapy among household contacts in a rural district of Malawi. Int J Tuberc Lung Dis. 2003;7:1033-1039.
38. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS. 2001;15:2137-2147.
39. Quigley MA, Mwinga A, Hosp M, et al. Longterm effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS. 2001;15:215-222.
40. Churchyard GJ, Fielding K, Charalambous S, et al. Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS. 2003;17:2063-2070.
41. Dye C, Floyd K. Tuberculosis. In: Jamison DT, Alleyne GAO, Breman JG, et al, eds. Disease Control Priorities in Developing Countries. 2nd ed. Washington, DC: Oxford University Press. In press.
42. Aisu T, Raviglione MC, Van Praag E, et al. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. AIDS. 1995;9:267-273.
43. Murray CJL, De Jonghe E, Chum HJ, Nyangulu DS, Salomao A, Styblo K. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet. 1991;338:1305-1308.
44. Volmink J, Garner P. Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment. BMJ. 1997;315:1403-1406.
45. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2003; Issue 1.
46. FIND Diagnostics. Available at: http://www.finddiagnostics.org. Accessed January 3, 2005.
47. Global Alliance for TB Drug Development. Scientific blueprint for tuberculosis drug development. Tuberculosis (Edinb). 2001;81(suppl 1):1-52.
48. Global Alliance for TB Drug Development Available at: http://www.tballiance.org. Accessed January 3, 2005.
49. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307:223-227.
50. Aeras Global TB Vaccine Foundation Available at: http://www.aeras.org. Accessed January 3, 2005.
51. Lietman T, Blower SM. Potential impact of tuberculosis vaccines as epidemic control agents. Clin Infect Dis. 2000;30:S316-S322.
52. Blower SM, McLean AR, Porco TC, et al. The intrinsic transmission dynamics of tuberculosis epidemics. Nat Med. 1995;1:815-821.
53. Dye C. Epidemiology. In: Davies PDO, ed. Clinical Tuberculosis. 3rd ed. London, England: Arnold; 2003.